EVIDENCE LIBRARY
Low-dose clobazam added after incomplete cenobamate response: an uncontrolled 85-patient series
A retrospective epilepsy cohort reported sustained seizure reductions but could not isolate the add-on drug’s causal contribution.
A retrospective epilepsy cohort reported sustained seizure reductions but could not isolate the add-on drug’s causal contribution.
The observed follow-up
Adults with focal drug-resistant epilepsy receiving cenobamate and continuing to have seizures were given adjunctive low-dose clobazam. Eighty-five patients were included. Median seizure reduction from clobazam initiation increased from 80% at three months to 95.8% at twelve months, and approximately one third achieved seizure freedom across follow-up.
Twelve-month retention was 83.1%. Reported adverse reactions were mainly mild to moderate, with somnolence prominent. Changes in other antiseizure medication burden were minor and descriptive.
No control group means several explanations remain
Natural fluctuation, regression to the mean, adherence changes, and other treatment effects could contribute. The study cannot establish that every improvement resulted from clobazam or that the combination is superior to all alternative additions. Seizure control and sleepiness are also separate outcomes.
For review, preserve the pretreatment seizure baseline, timing of add-on treatment, co-medication, and follow-up completeness. The paper provides a real-world signal warranting further study, not a universal dosing or safety rule.
Source paper
Original analysis of the supplied journal article, identified as PMC13238903.